Overview
Treatments, in the context of coronavirus disease, comprise the pharmacological and supportive interventions used to reduce symptoms, limit disease progression, and lower mortality in infected patients. They span several mechanistic categories: direct-acting antivirals that interfere with viral replication; immunomodulatory agents, including interferons and anti-inflammatory drugs, that temper the dysregulated host response driving severe illness; repurposed compounds evaluated in clinical trials; and supportive and rehabilitative care for critically ill patients, such as those recovering in intensive-care settings. Research in this area assesses candidate therapies through controlled studies measuring clinical improvement and survival, recognizing that early observational enthusiasm for some agents has required rigorous testing to confirm or refute benefit. The trajectory of COVID-19 therapeutics illustrates the broader principle that new drugs, treatments, and devices must undergo clinical evaluation before adoption, because efficacy and safety cannot be assumed from mechanism alone. Investigators also explore adjunctive and complementary approaches and the role of host-directed strategies. Selecting appropriate treatment depends on disease severity, timing within the illness course, and patient risk factors. As an evolving field, coronavirus treatment integrates virology, immunology, pharmacology, and clinical trial methodology to build an evidence base that distinguishes interventions that genuinely improve outcomes from those that do not.
Research published in this journal
6 peer-reviewed articles, ranked by relevance. Each links to its DOI.
Anti-Oxidant Phytochemicals as Potential Treatments for Age-Related Macular Degeneration
Complementary and Alternative Treatments for Cancer Prevention and Cure (Part 1)
Use of Immune Modulator Interferon-Gamma to Support Combating COVID-19 Pandemic
Progress in Rehabilitation Treatments for Sepsis Patients in ICU
Why New Drugs, Treatments, and Medical Devices Still Needs to be Tested Clinically Before Making it Available in the Market?
How this research is being cited
The 6 articles above have been cited 30 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2025 · Journal of Biomolecular Structure and Dynamics
-
2025 · Inflammopharmacology
-
2025 · Inflammopharmacology
-
2023 · Journal of Biomolecular Structure and Dynamics
-
Jaekwon Seok et al. · 2023 · Journal of Translational Medicine
-
2023 · Frontiers in Medicine
-
2023 · Frontiers in Medicine
-
2022 · Acta Ophthalmologica
A sample of recent works citing this journal's research on Treatments, linking to each citing work.